Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study

Alessandro Rambaldi (1) , Alessandra Iurlo , Alessandro M. Vannucchi (2) , Richard Noble (3) , Nikolas Von Bubnoff , Attilio Guarini , Bruno Martino (4) , Antonio Pezzutto , Giuseppe Carli , Marianna de Muro , Stefania Luciani , Mary Frances Mcmullin (5) , Nathalie Cambier (6) , Jean-Pierre Marolleau (7, 8) , Ruben A. Mesa , Raoul Tibes , Alessandro Pancrazzi (9) , Francesca Gesullo , Paolo Bettica , Sara Manzoni , Silvia Di Tollo

1 UNIMI - Università degli Studi di Milano = University of Milan
2 UF di Ematologia, Dip. Area Critica
3 University of Warwick [Coventry]
4 Hematology
5 QUB - Queen's University [Belfast]
6 Centre hospitalier [Valenciennes, Nord]
7 CHU Amiens-Picardie
8 HEMATIM - HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666
9 Centro di Ricerca e Innovazione per le Malattie Mieloproliferative - CRIMM [ Florence, Italy]

Domaines: Sciences du Vivant [q-bio]

Alessandro Rambaldi, Alessandra Iurlo, Alessandro M. Vannucchi, Richard Noble, Nikolas Von Bubnoff, et al.. Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Leukemia, 2020, 34 (8), pp.2234-2237. ⟨10.1038/s41375-020-0735-y⟩. ⟨hal-03604943⟩